KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Assets: 2011-2024

Historic Assets for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to $594.1 million.

  • Travere Therapeutics' Assets rose 6.77% to $538.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $538.6 million, marking a year-over-year increase of 6.77%. This contributed to the annual value of $594.1 million for FY2024, which is 24.69% down from last year.
  • Latest data reveals that Travere Therapeutics reported Assets of $594.1 million as of FY2024, which was down 24.69% from $788.9 million recorded in FY2023.
  • Over the past 5 years, Travere Therapeutics' Assets peaked at $788.9 million during FY2023, and registered a low of $594.1 million during FY2024.
  • In the last 3 years, Travere Therapeutics' Assets had a median value of $672.6 million in 2022 and averaged $685.2 million.
  • As far as peak fluctuations go, Travere Therapeutics' Assets rose by 27.85% in 2021, and later declined by 24.69% in 2024.
  • Over the past 5 years, Travere Therapeutics' Assets (Yearly) stood at $607.4 million in 2020, then grew by 27.85% to $776.6 million in 2021, then decreased by 13.40% to $672.6 million in 2022, then increased by 17.30% to $788.9 million in 2023, then decreased by 24.69% to $594.1 million in 2024.